Despite functioning as a tumor suppressor gene in early B-cell development [11], [19], IRF4 is a well-established oncogene in multiple myeloma (MM) [20], with oncogenic implications extending to certain adult lymphomas and leukemias [13], [21]–[23]. The gene discussed is IRF4; the disease is Miyoshi myopathy.